参考文献/References:
[1]Das M,Zhu C,KuchrooVK.Tim-3 and its role in regulating anti-tumor immunity[J].Immunol Rev,2017,276(1):97-111.[2]Solinas C,de Silva P,Bron D,et al.Significance of TIM3 expression in cancer: from biology to the clinic[J].Semin Oncol,2019,46(4-5):372-379.[3]He YY,Cao J,Zhao C,et al.TIM-3, a promising target for cancer immunotherapy[J].Onco Targets Ther,2018,11:7005-7009.[4]Sheng CC,Han FY.Immunoregulation effects of TIM-3 on tumors[J].Neoplasma,2019,66(2):167-175.[5]Gao X,Zhu YB,Li G,et al.TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression[J].PLoS One,2012,7(2):e30676.[6]吉芃,陈迪康,卞建叶,等.TIM-3在人非小细胞肺癌CD4+肿瘤浸润淋巴细胞的表达增强提示预后不良[J].细胞与分子免疫学杂志,2015,31(6):808-811.[7]Zhou GY,Sprengers D,Boor PPC,et al.Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cellsin hepatocellular carcinomas[J].Gastroenterology,2017,153(4):1107-1119.[8]Takano S,Saito H,Ikeguchi M.An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer[J].Surg Today,2016,46(11):1341-1347.[9]Piao YR,Jin XS.Analysis of Tim-3 as a therapeutic target in prostate cancer[J].Tumour Biol,2017,39(7):1010428317716628.[10]Zhang W,Feng H,Chen QC,et al.The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer[J].Exp Cell Res,2018,372(2):92-98.[11]Li XE,Wang B,Gu LT,et al.Tim-3 expression predicts the abnormal innate immune status and poor prognosis of glioma patients[J].Clin Chim Acta,2018,476:178-184.[12]郑雨佳,杨惠雲,吴倩,等.Tim-3在食管癌患者T细胞表面的表达及其临床意义[J].中国肿瘤生物治疗杂志,2019,26(3):312-316.[13]Xu BL,Yuan L,Gao QL,et al.Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer[J].Oncotarget,2015,6(24):20592-20603.[14]Gravelle P,Do C,Franchet C,et al.Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement[J].Oncoimmunology,2016,5(10):e1224044.[15]Li Z,Li N,Li F,et al.Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma[J].Medicine (Baltimore),2016,95(52):e5749.[16]Wang YY,Wang SC,Zhu CC,et al.The association between immune characteristic and clinical pathology in Chinese patients with adenocarcinoma of esophagogastric junction[J].Cancer Manag Res,2020,12:3259-3269.[17]Liu ZJ,Han HM,He X,et al.Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma[J].Oncol Lett,2016,11(3):1829-1834.[18]Moore M,Ring KL,Mills AM.TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers[J].Mod Pathol,2019,32(8):1168-1179.[19]Curley J,Conaway MR,Chinn Z,et al.Looking past PD-L1:expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia[J].Mod Pathol,2020,33(6):1182-1192.[20]Yu MM,Lu B,Liu YC,et al.Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression[J].Mol Med Rep,2017,15(2):689-695.[21]Sun QY,Qu CH,Liu JQ,et al.Down-regulated expression of Tim-3 promotes invasion and metastasis of colorectal cancer cells[J].Neoplasma,2017,64(1):101-107.[22]Wu JL,Lin GW,Zhu Y,et al.Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status[J].Sci Rep,2017,7(1):8869.[23]Zhang XM,Yin XX,Zhang HR,et al.Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma[J].BMC Cancer,2019,19(1):49.[24]Peng PJ,Li Y,Sun S.On the significance of Tim-3 expression in pancreatic cancer[J].Saudi J Biol Sci,2017,24(8):1754-1757.[25]郑雨佳,杨惠雲,吴倩,等.Tim-3在食管癌患者T细胞表面的表达及其临床意义[J].中国肿瘤生物治疗杂志,2019,26(3):312-316.[26]张季,邹陈蔚,仓慧,等.Tim-3在食管癌中的表达及其临床意义[J].胃肠病学,2020,25(9):540-543.[27]Quan HZ,Fang LJ,Pan H,et al.An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma[J].Int J Cancer,2016,138(12):2952-2962.[28]Liu JF,Ma SR,Mao L,et al.T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer[J].Mol Oncol,2017,11(2):235-247.[29]Cheng SQ,Han FY,Xu YQ,et al.Erratum: Expression of Tim-3 in breast cancer tissue promotes tumor progression[J].Int J Clin Exp Pathol,2021,14(7):855.[30]高锋,钱文霞,冯一中.非小细胞肺癌中TIM-3、PD-1、PD-L1的表达与临床意义[J].海南医学,2019,30(2):154-158.[31]Fang HY,YuanC,Gu XS,et al.TIM-3Association between polymorphisms and cancer risk:a meta-analysis[J].Ann Transl Med,2019,7:550.[32]Cui SJ,Li Y,Zhou RM,et al.TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression[J].Environ Mol Mutagen,2021,62(4):273-283.[33]Liu YB,Duan Y,Yang N,et al.The TIM-3 Rs10053538 polymorphism is associated with clinical prognosis of colorectal cancer[J].Immunol Invest,2022,51(5):1302-1312.[34]Wu JL,Zhao J,Zhang HB,et al.Genetic variants and expression of the TIM-3 gene are associated with clinical prognosis in patients with epithelial ovarian cancer[J].Gynecol Oncol,2020,159(1):270-276.[35]Cong YZ,Liu J,Chen G,et al.The emerging role of T-cell immunoglobulin mucin-3 in breast cancer: apromising target for immunotherapy[J].Front Oncol,2021,11:723238.[36]Saleh R,Taha RZ,Toor SM,et al.Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer[J].CancerImmunolImmunother,2020,69(10):1989-1999.[37]沈辉,盛晗,陆建菊,等.程序性死亡受体1和T细胞免疫球蛋白黏蛋白分子3在乳腺癌肿瘤微环境中的表达、分布及其与临床病理特征的关系[J].中华医学杂志,2018,98(17):1352-1357.[38]Cao Y,Zhou XX,Huang XY,et al.Tim-3 expression in cervical cancer promotes tumor metastasis[J].PLoS One,2013,8(1):e53834.[39]郭艳,魏小娟,高琦.T细胞中Tim-3异常表达对胃癌进展的调控机制[J].中国老年学杂志,2021,41(21):4834-4837.[40]Chen BJ,Dashnamoorthy R,Galera P,et al.The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma[J].Oncotarget,2019,10(21):2030-2040.[41]Sakuishi K,Apetoh L,Sullivan J,et al.Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity[J].J Exp Med,2011,208(6):1331.[42]Liu Y,Cai PC,Wang N,et al.Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma[J].Biochem Biophys Res Commun,2017,484(2):378-384.
相似文献/References:
[1]杨森果,毛大华,杨海松,等.E-cadherin与肿瘤侵袭、转移相关性研究进展[J].医学信息,2018,31(03):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
YANG Sen-guo,MAO Da-hua,YANG Hai-song,et al.Research Progress of the Correlation between E-cadherin and Tumor Invasion and Metastasis[J].Journal of Medical Information,2018,31(17):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
[2]江立基,李先明.碳酸酐酶Ⅸ在肿瘤中的研究进展[J].医学信息,2018,31(03):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
JIANG Li-ji,LI Xian-ming.Research Progress of Carbonic Anhydrase IX in Cancer[J].Journal of Medical Information,2018,31(17):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(17):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]白 雪,邓 琦.血液系统肿瘤的细胞治疗研究进展[J].医学信息,2018,31(10):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
BAI Xue,DENG Qi.Advances in Cell Therapy for Blood System Tumor[J].Journal of Medical Information,2018,31(17):41.[doi:10.3969/j.issn.1006-1959.2018.10.013]
[5]李 轩,王子为,赵靖萱,等.肿瘤预后预测领域机器学习应用的文献计量与热点可视化分析[J].医学信息,2022,35(09):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
LI Xuan,WANG Zi-wei,ZHAO Jing-xuan,et al.Visualization Analysis on Bibliometrics and Hot Spots of Machine Learning Applications in the Field of Tumor Prognosis Prediction[J].Journal of Medical Information,2022,35(17):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
[6]王 静,刘 梅,焦菊凤.知-信-行健康教育模式对PICC置管肿瘤
患者自我护理能力的影响[J].医学信息,2018,31(11):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
WANG Jing,LIU Mei,JIAO Ju-feng.Effect of Knowledge-belief-behavioral Health Education Model on the Self-care Ability of Patients with Cancer in PICC Catheterization[J].Journal of Medical Information,2018,31(17):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
[7]史红娟,李群锋,赵 华,等.舒林酸抗肿瘤作用的研究进展[J].医学信息,2018,31(12):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
SHI Hong-juan,LI Qun-feng,ZHAO Hua,et al.Advances in Research on Anti-tumor Effect of Sulindac[J].Journal of Medical Information,2018,31(17):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
[8]庞小坤,韩 梅,江心灿,等.当归补血汤治疗肿瘤化疗不良反应随机对照临床试验的Meta分析[J].医学信息,2019,32(02):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
Pang Xiao-kun,Han Mei,Jiang Xin-can,et al.Meta-analysis of a Randomized Controlled Clinical Trial of Angelica Buxue Decoction in the Treatment of Adverse Reactions to Chemotherapy[J].Journal of Medical Information,2019,32(17):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
[9]张 慧,胡广越,殷 红.菌群干预与免疫治疗的研究进展[J].医学信息,2022,35(11):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
ZHAHG Hui,HU Guang-yue,YIN Hong.Research Progress in Microbial Intervention and Immunotherapy[J].Journal of Medical Information,2022,35(17):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
[10]郑文灿,法艳梅,吕亚青,等.苦参碱抗肿瘤机制的分子生物学研究进展[J].医学信息,2018,31(19):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
ZHENG Wen-can,FA Yan-mei,LV Ya-qing,et al.Advances in Molecular Biology of Matrine Antitumor Mechanism[J].Journal of Medical Information,2018,31(17):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]